Nothing Special   »   [go: up one dir, main page]

ATE385503T1 - Verfahren zur modulierung von integrin- vermittelter zellaktivitaet und hierfuer geeignete reagenzien - Google Patents

Verfahren zur modulierung von integrin- vermittelter zellaktivitaet und hierfuer geeignete reagenzien

Info

Publication number
ATE385503T1
ATE385503T1 AT00940024T AT00940024T ATE385503T1 AT E385503 T1 ATE385503 T1 AT E385503T1 AT 00940024 T AT00940024 T AT 00940024T AT 00940024 T AT00940024 T AT 00940024T AT E385503 T1 ATE385503 T1 AT E385503T1
Authority
AT
Austria
Prior art keywords
cell activity
mediated cell
reagents suitable
integrin
modulating
Prior art date
Application number
AT00940024T
Other languages
English (en)
Inventor
Michael Agrez
Nuzhat Ahmed
Original Assignee
Inter K Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPQ1248A external-priority patent/AUPQ124899A0/en
Priority claimed from AUPQ8003A external-priority patent/AUPQ800300A0/en
Application filed by Inter K Pty Ltd filed Critical Inter K Pty Ltd
Application granted granted Critical
Publication of ATE385503T1 publication Critical patent/ATE385503T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT00940024T 1999-06-28 2000-06-28 Verfahren zur modulierung von integrin- vermittelter zellaktivitaet und hierfuer geeignete reagenzien ATE385503T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPQ1248A AUPQ124899A0 (en) 1999-06-28 1999-06-28 A method of treatment and agents useful for same
AUPQ8003A AUPQ800300A0 (en) 2000-06-06 2000-06-06 A method of treatment and agents useful for same

Publications (1)

Publication Number Publication Date
ATE385503T1 true ATE385503T1 (de) 2008-02-15

Family

ID=25646086

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00940024T ATE385503T1 (de) 1999-06-28 2000-06-28 Verfahren zur modulierung von integrin- vermittelter zellaktivitaet und hierfuer geeignete reagenzien

Country Status (5)

Country Link
US (2) US8119594B1 (de)
EP (1) EP1196449B1 (de)
AT (1) ATE385503T1 (de)
DE (1) DE60037970T2 (de)
WO (1) WO2001000677A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE385503T1 (de) 1999-06-28 2008-02-15 Inter K Pty Ltd Verfahren zur modulierung von integrin- vermittelter zellaktivitaet und hierfuer geeignete reagenzien
DE10027777A1 (de) * 2000-06-07 2001-12-13 Otogene Ag Transfektionsverfahren
AUPR230500A0 (en) * 2000-12-22 2001-01-25 University Of Newcastle Research Associates Limited, The A method of modulating map kinase mediated cellular activity and agents useful in same
US9200036B2 (en) 2002-07-12 2015-12-01 The Johns Hopkins University Mesothelin vaccines and model systems
AU2004281077B2 (en) 2003-10-17 2010-12-02 Inter-K Pty Limited Methods and agents for the treatment of cancer
US20110105408A1 (en) * 2008-02-22 2011-05-05 Inter-K Pty Limited Therapeutic peptides
ES2528209T3 (es) 2008-03-31 2015-02-05 Council Of Scientific & Industrial Research Sistema modelo de tumor útil para estudiar el cáncer polietápico
AU2010215086A1 (en) * 2009-02-23 2011-09-08 Inter-K Pty Limited Inhibition of multiple cell activation pathways
JP6249447B2 (ja) * 2012-01-24 2017-12-20 インターケー・ペプチド・セラピューティクス・リミテッド 癌治療用ペプチド剤

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE911869A1 (en) 1990-06-01 1991-12-04 Regeneron Pharma A family of map2 protein kinases
US5177188A (en) * 1990-12-03 1993-01-05 The Scripps Research Institute Methods and compositions for diagnosing chronic immune thrombocytopenic purpura
WO1992012236A1 (en) * 1991-01-11 1992-07-23 The Regents Of The University Of California A NOVEL INTEGRIN β SUBUNIT AND USES THEREOF
US5962643A (en) 1991-07-11 1999-10-05 The Regents Of The University Of California Integrin β subunit and uses thereof
US6514745B1 (en) 1993-07-19 2003-02-04 The Regents Of The University Of California Oncoprotein protein kinase
US6495518B1 (en) 1994-06-13 2002-12-17 Vanderbilt University Method for importing biologically active molecules into cells
US5807746A (en) 1994-06-13 1998-09-15 Vanderbilt University Method for importing biologically active molecules into cells
US5877282A (en) 1996-09-20 1999-03-02 Bristol-Myers Squibb Company Peptide inhibitors of nuclear protein translocation having nuclear localization sequences and methods of use thereof
AU4815397A (en) 1996-10-15 1998-05-11 Vanderbilt University Method of disrupting cellular adhesion
US6007991A (en) 1997-03-28 1999-12-28 The Research Foundation Of Suny Antisense oligonucleotides for mitogen-activated protein kinases as therapy for cancer
US6133246A (en) 1997-08-13 2000-10-17 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
US5877309A (en) 1997-08-13 1999-03-02 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against JNK
US6248558B1 (en) 1998-03-31 2001-06-19 Vanderbilt University Sequence and method for genetic engineering of proteins with cell membrane translocating activity
WO1999053032A1 (en) * 1998-04-15 1999-10-21 Cor Therapeutics, Inc. TRANSGENIC MAMMALS EXPRESSING MUTANT GP IIIa
ATE385503T1 (de) 1999-06-28 2008-02-15 Inter K Pty Ltd Verfahren zur modulierung von integrin- vermittelter zellaktivitaet und hierfuer geeignete reagenzien
US6312956B1 (en) 1999-10-01 2001-11-06 Vanderbilt University Nuclear targeted peptide nucleic acid oligomer
EP1303287A4 (de) * 2000-06-16 2006-02-08 Argonex Pharmaceuticals In prostata-krebszellen überexprimierte mhc-peptide und methoden zu deren verwendung
US7198895B2 (en) * 2000-11-14 2007-04-03 Mohanlal Ramon W In vitro cell-based methods for biological validation and pharmacological screening of chemical entities and biologicals

Also Published As

Publication number Publication date
US8618062B2 (en) 2013-12-31
US8119594B1 (en) 2012-02-21
US20120232249A1 (en) 2012-09-13
EP1196449A4 (de) 2004-06-16
DE60037970T2 (de) 2008-08-21
DE60037970D1 (de) 2008-03-20
EP1196449A1 (de) 2002-04-17
WO2001000677A1 (en) 2001-01-04
WO2001000677A9 (en) 2002-11-07
EP1196449B1 (de) 2008-02-06

Similar Documents

Publication Publication Date Title
ATE395934T1 (de) Verfahren zur inhibierung von gehirntumorwachstum durch verwendung von antagonisten von integrinen
DE60001478D1 (de) Verfahren sowie Vorrichtung zur Aktualisierung von Widerrufungsinformation, und Speichermedium
DE19983231T1 (de) System und Verfahren zur Sekundärförderung von Kohlenwasserstoff
WO2001038532A3 (en) Reagents and methods for identifying and modulating expression of genes regulated by cdk inhibitors
DE69809263D1 (de) Methoden ud system zur wahl von datensets
DE69736669D1 (de) Zelladhäsionsinhibitoren
DE69923657T8 (de) Markierung von gespeicherten datenobjekten für garbage-kollektoren
DE60035183D1 (de) System und verfahren zur entdeckung von mitteln unter verwendung von mehrfachübertragungsumfang
DE69740113D1 (de) Vorrichtung und verfahren zur inkubation von zellen
DE69924772D1 (de) System und Endgerät zur Bereitstellung von Karteninformationen
DE69815085D1 (de) System und verfahren zur klassifizierrung von zellproben
DE60231978D1 (de) Verfahren und systeme zur verminderung von störungen über abdeckzellen hinweg
DE60037370D1 (de) Sinusförmiges Zellkulturmodul zur Kultivierung von Hepatozyten
DE69919151D1 (de) Verfahren zur synthese von cox-2 inhibitoren
DE50013547D1 (de) Verfahren zur Anzeige von Primär-und Sekundärinformationen
DE69931775D1 (de) Verfahren zur verbesserung der deckung in mehrzellkommunakationssystemen unter verwendung von aufenthaltsortsinformationen
ATE385503T1 (de) Verfahren zur modulierung von integrin- vermittelter zellaktivitaet und hierfuer geeignete reagenzien
DE69738045D1 (de) Verwendung von cetrorelix zur behandlung von benigne prostatahypertrophie und prostatakrebs
DE60029947D1 (de) System und verfahren für joint-time-tracking von mehrfachen pfaden
DE69925333D1 (de) Zur richtigen Ausführung von Heft- und Lochungsoperationen geeignetes Bildformgerät
DE50015264D1 (de) Anordnung zur Selbstreferenzierung von ferroelektrischen Speicherzellen
DE69800720D1 (de) Reagenz zur Färbung von Blutzellen
DE60002275D1 (de) System zur Erzeugen von Quadratursignalen
DE60136251D1 (de) Verfahren zur verminderung von interferenzeffekten und funksystem
DE60124780D1 (de) Vorrichtung und verfahren zur serienvermehrung von säugerzellen zum animpfen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1196449

Country of ref document: EP